TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03745508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instant Coffee
Description: Instant coffee prepared at different caffeine concentrations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instant Coffee
Description: Instant coffee prepared at different caffeine concentrations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Instant Coffee
Description: Instant coffee prepared at different caffeine concentrations
Study: NCT03279081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cx601
Description: Cx601 eASCs intralesional injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cx601 placebo-matching eASCs intralesional injection.
Study: NCT05130580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Consultation
Description: Attend an enhanced consultation with decision aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Consultation
Description: Attend standard of care consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Imaging
Description: Undergo 2D and 3D torso imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Imaging
Description: Undergo 2D and 3D torso imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03913533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method
Description: Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate assessment using Tap-based smartphone application
Description: At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
Study: NCT01581801

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric Bypass
Description: Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sleeve Gastrectomy
Description: Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
Study: NCT03755934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion of placebo as stated in arm description.
Study: NCT01932593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of autologous bone marrow
Description: Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of autologous bone marrow
Description: Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
Study: NCT00307801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Study: NCT03889223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical intervention with USG and comfort evaluation with NRS
Description: The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical intervention with USG and comfort evaluation with NRS
Description: The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
Study: NCT01318577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Cleaning & Disinfecting Solution
Description: Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care Solution
Description: Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
Study: NCT03361800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: oral drug, 5mg tablet given once weekly x 2 doses
Study: NCT01056822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1
Description: Continue with same dose of MMF as patient was taking before randomisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2
Description: Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
Study: NCT00762164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin 10/80 split into 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 milligrams
Study: NCT04069234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 60 mg BID for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75mg OD for 30 Days
Study: NCT04524949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 450 μg
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 1350 μg
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solvent: alum hydroxide
Study: NCT02364375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (full face)
Description: Prototype mask system (full face variant) with novel vent and humidification system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (full face)
Description: Prototype mask system (full face variant) with conventional vent and humidification system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (nasal)
Description: Prototype mask system (nasal variant) with novel vent and humidification system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (nasal)
Description: Prototype mask system (nasal variant) with conventional vent and humidification system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai mask (pillows)
Description: Prototype mask system (pillows variant) with conventional vent and humidification system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menai Standard mask (pillows)
Description: Prototype mask system (pillows variant) with conventional vent and humidification system
Study: NCT04169035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.
Description: The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forceps or ventouse
Description: The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body.
Study: NCT02700321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIFLOW/ AIRVO
Description: Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD Face Mask
Description: Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction.
Study: NCT04362241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: Prednisolone Acetate 1% ophthalmic drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: Prednisolone Acetate 1% ophthalmic drops
Study: NCT02167698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Description: This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-tidal volume ventilation
Description: This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Description: Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy
Description: Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedo-analgesia titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedo-analgesia titration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized early enteral nutrition
Description: Early enteral nutrition and attempt to meet calorie-protein goals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized early enteral nutrition
Description: Early enteral nutrition and attempt to meet calorie-protein goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized supportive care
Description: Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized supportive care
Description: Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Assay
Description: Biomarker Assay for patients in both arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Assay
Description: Biomarker Assay for patients in both arms
Study: NCT04375891

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: 30 Gy in 10 fractions of 3 Gy each

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: 30 Gy in 10 fractions of 3 Gy each

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiofrequency Ablation (RFA)
Description: Radiofrequency Ablation (RFA) / Vertebral Augmentation
Study: NCT00979940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80mg po given one time before PCI in cath lab.
Study: NCT02677441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative management
Description: Specific standardized rehabilitation protocol under Cote et al (2010)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
Study: NCT03481400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin Gene-Related Peptide
Description: Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Isotonic saline
Study: NCT03153592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure driven ventilation strategy
Description: Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation strategy
Description: 13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
Study: NCT04142931

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ImmunicomAIAC
Description: filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ImmunicomAIAC
Description: filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
Study: NCT01668784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study: NCT03779009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)
Description: Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
Study: NCT03756519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice to stay active and engaged in usual activities.
Description: Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice to stay active and engaged in usual activities.
Description: Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice on use of ice or heat
Description: Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on use of ice or heat
Description: Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advise regarding use of medications
Description: Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advise regarding use of medications
Description: Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
Study: NCT03041740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfluorooctyl Bromide
Description: Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
Study: NCT02575586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control-Dry Needling
Description: Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times.
Study: NCT04500912

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supraflex Cruz 60 Micron
Description: percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultimaster Tansei 80 Micron
Description: percutaneous coronary intervention
Study: NCT02684851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01971710

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community leader engagement
Description: Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community leader engagement
Description: Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community leader engagement
Description: Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community days
Description: The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community days
Description: The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Peer Groups
Description: Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
Study: NCT03213860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China
Description: The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
Study: NCT04080908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol injection
Description: Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
Study: NCT05033171

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Scanning
Description: 3D scanning of the rod using Artec Eva Spider type manual 3D scanner
Study: NCT03933007

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine,
Description: the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)

Intervention type: DRUG
Group type: OTHER
Intervention: midazolam,
Description: Midazolam 1 mg

Intervention type: DRUG
Group type: OTHER
Intervention: fexofenadine
Description: Fexofenadine 120 mg
Study: NCT01394016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered intramuscularly into the buttocks in Part G only.
Study: NCT03059849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Dose of adalimumab will be increased by 40mg every 2 weeks.